News | October 13, 2022
Piramal Pharma Solutions launches ADCelerate
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The GMP certificate is valid for three years until April 2024.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
With standout ADC and t-cell engager response data across hard-to-treat cancers
Subscribe To Our Newsletter & Stay Updated
